For investors in 2026, buying dividend stocks has become a major theme. Their value lies not only in the recurring income they generate but also in their stability—they are often viewed as relatively safe investments to hold for the long term. However, when a stock offers a dividend yield as high as 4.4%, far above the S&P 500 average of 1.2%, investors may need to ask: Is this payout really secure?
Bristol Myers Squibb (BMY) is exactly the kind of healthcare stock that catches the eye. As a leader in the sector, its current yield of 4.4% is highly attractive in today’s market environment. On the surface, it looks like a no-brainer dividend pick.
But there is a common mistake investors make when evaluating dividend stocks: putting too much weight on historical track records. No matter how impressive a company’s dividend growth streak may be, streaks can be broken. Dividend policies can change—especially when a company faces headwinds and needs to direct cash to more urgent priorities.
Bristol Myers Squibb faces a challenging road ahead. The company is approaching patent expirations on several key drugs in the coming years, including the blockbuster anticoagulant Eliquis and the prominent oncology drug Opdivo.
As generic competition intensifies, the company’s revenue could take a hit, leading to lower earnings and reduced free cash flow—both of which directly threaten its ability to maintain dividend payments. To mitigate the impact of these patent losses, the company may also feel compelled to pursue acquisitions, adding further pressure on its cash position.
In fact, the pressure is already visible. Last year, the company’s revenue was flat at $48.2 billion. This year, it has guided for revenue in the range of $46 billion to $47.5 billion, signaling a potential decline.
On paper, Bristol Myers still looks like an ideal dividend investment: 17 consecutive years of dividend increases, a manageable payout ratio of 72%, and an attractive high yield.
Yet the significant uncertainty surrounding the business cannot be ignored. While a dividend cut or suspension is not inevitable, it is a real possibility depending on how the company navigates the next few years. For a truly ideal dividend stock, investors want a “buy-and-forget” asset—one they don’t have to worry about. By that standard, Bristol Myers Squibb does not yet qualify.
Amid heightened market volatility driven by trade tensions and geopolitical uncertainty, concerns over inflation, a potential market downturn, or even a recession are weighing on investors. In such an environment, companies with resilient business models certainly deserve attention.
But the story of Bristol Myers Squibb serves as a reminder: a high dividend yield is enticing, but the underlying fundamentals that support that payout are what ultimately matter. With the patent cliff looming, whether this 4.4% dividend remains sustainable is a question that only time can answer.
